Key clinical considerations for demonstrating the utility of preclinical models to predict clinical drug‐induced torsades de pointes
Author:
- 1 August 2008
- journal article
- review article
- Published by Wiley in British Journal of Pharmacology
- Vol. 154 (7) , 1544-1549
Abstract
While the QT/QTc interval is currently the best available clinical surrogate for the development of drug‐induced torsades de pointes, it is overall an imperfect biomarker. In addition to low specificity for predicting arrhythmias, other issues relevant to using QT as a biomarker include (1) an apparent dissociation, for some drugs (for example, amiodarone, sodium pentobarbital, ranolazine) between QT/QTc interval prolongation and TdP risk, (2) Lack of clarity regarding what determines the relationship between QTc prolongation and TdP risk for an individual drug, (3) QT measurement issues, including effects of heart rate and autonomic perturbations, (4) the significant circadian changes to the QT/QTc interval and (5) concerns that the development, regulatory and commercial implications of finding even a mild QT prolongation effect during clinical development has significant impact the pharmaceutical discovery pipeline. These issues would be significantly reduced, clinical development simplified and marketing approval for some drugs might be accelerated if there were a battery of preclinical tests that could reliably predict a drug's propensity to cause TdP in humans, even in the presence of QTc interval prolongation. This approach is challenging and for it to be acceptable to pharmaceutical developers, the scientific community and regulators, it would need to be scientifically well validated. A very high‐negative predictive value demonstrated in a wide range of drugs with different ionic effects would be critical. This manuscript explores the issues surrounding the use of QT as a clinical biomarker and potential approaches for validating preclinical assays for this purpose against clinical data sets. British Journal of Pharmacology (2008) 154, 1544–1549; doi:fn1; published online 9 June 2008Keywords
This publication has 26 references indexed in Scilit:
- Ranexa (ranolozaine)PharmaDeals Review, 2006
- Use of preclinical assays to predict risk of drug-induced torsades de pointesHeart Rhythm, 2005
- ICH E14: A New Regulatory Guidance on the Clinical Evaluation of QT/QTc Internal Prolongation and Proarrhythmic Potential for Non-antiarrhythmic DrugsDrug Information Journal, 2005
- Drug-Induced Prolongation of the QT IntervalNew England Journal of Medicine, 2004
- Electrophysiologic Properties and Antiarrhythmic Actions of a Novel Antianginal AgentJournal of Cardiovascular Pharmacology and Therapeutics, 2004
- Assessing predictors of drug-induced torsade de pointesTrends in Pharmacological Sciences, 2003
- Spectrum of drugs prolonging QT interval and the incidence of torsades de pointesEuropean Heart Journal Supplements, 2001
- The QT interval☆Progress in Cardiovascular Diseases, 2001
- Evaluation of Drug-Induced QT Interval ProlongationDrug Safety, 2001
- Pharmacokinetic and pharmacodynamic effects of high-dose continuous intravenous verapamil infusionCritical Care Medicine, 1999